Picture Swiss Biotech Association LSUS Global Village 2025 Basel 650x100px

Organisation › Details

CBER (FDA)

	Start	1992-07-01 existent
	Group	United States (govt)

	Region	United States (USA)_oo
	Country	United States (USA)
	City	n. a.
		Address record changed: 2011-05-15

Basic data	Employees	n. a.


		Record changed: 2024-05-30

Picture Kenes Exhibitions Biomed Israel 2025 Tel Aviv 650x200px

More documents for United States (govt)

[1] Immatics N.V.. (10/10/24). "Press Release: Immatics Announces Updated Phase 1b Clinical Data on ACTengine IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial". Houston, TX & Tübingen....
[2] Medigene AG. (9/5/24). "Press Release: Medigene Announces U.S. FDA Clearance of IND Application for MDG1015 for Multiple Solid Tumor Indications". Planegg....
[3] Bavarian Nordic A/S. (8/8/24). "Press Release: Bavarian Nordic Receives USD 156.8 Million from the U.S. Government for Additional Smallpox/Mpox Vaccine Production". Copenhagen....
[4] Karius, Inc.. (8/8/24). "Press Release: Karius Secures BARDA Contract to Expand Agnostic Detection of Pathogens". Redwood City, CA....
[5] Adaptimmune Therapeutics plc. (8/1/24). "Press Release: Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor". Philadeliphia, PA & Oxford....
[6] Full-Life Technologies. (7/3/24). "Press Release: Full-Life Technologies Granted FDA Fast Track Designation for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer". Heidelberg....
[7] Evotec SE. (6/25/24). "Press Release: Just – Evotec Biologics Selected by U.S. Department of Defense for Manufacturing Optimization Program". Hamburg....
[8] InflaRx N.V.. (6/24/24). "Press Release: InflaRx’s Gohibic (vilobelimab) Selected for First BARDA-sponsored Clinical Trial to Evaluate Novel Host-directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)". Jena....
[9] BioNTech SE. (6/24/24). "Press Release: BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer". Mainz & Shanghai....
[10] BlueRock Therapeutics LP. (5/30/23). "Press Release: BlueRock Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for Parkinson’s Disease Cell Therapy Candidate Bemdaneprocel". Berlin & Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]